Clinical Evaluation of Ramosetron Injections in the Treatment of Cisplatin-induced Nausea and Vomiting  

Oleh:

Noda, K ; Yoshida, O ; Ikeda, M

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 30 no. 03 (May 2002), page 211-219.
Topik: ramosetron; cisplatin; CDDP; 5-HT3 receptor antagonist; cancer chemotherapy; anti-emesis; safety; efficacy

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A phase III, double-blind, placebo-controlled study was performed to examine the safety and efficacy of ramosetron in cancer patients with cisplatin-induced nausea/vomiting. Patients were divided into two groups: group R received 0.3 mg ramosetron intravenously and group P received placebo. Eighty-eight patients were enrolled, 44 in each group; 84 (43 in group R, 41 in group P) were included in the clinical efficacy analysis and 86 (44 in group R, 42 in group P) in the safety analysis. Ramosetron was significantly more clinically effective than placebo against nausea, vomiting and anorexia; 65.1% of patients in group R experienced no vomiting in the first 6 h of observation compared with 7.3% of those receiving placebo. No serious adverse reactions or significant differences in safety were observed between the groups. Based on these results, ramosetron injection is effective in the treatment of cisplatin-induced nausea/vomiting and its clinical usefulness is demonstrated here.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali